PacBio Files 8-K/A Amendment on Leadership Changes
Ticker: PACB · Form: 8-K/A · Filed: Dec 13, 2024 · CIK: 1299130
Sentiment: neutral
Topics: leadership-change, executive-compensation, amendment
Related Tickers: PACB
TL;DR
**PacBio amends 8-K, signaling leadership shifts and exec comp changes.**
AI Summary
Pacific Biosciences of California, Inc. filed an amendment (8-K/A) on November 11, 2024, related to the departure of directors, election of directors, appointment of officers, and compensatory arrangements. The filing details changes within the company's leadership and executive compensation structure.
Why It Matters
This amendment provides updated information on the company's board of directors and executive officers, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings concerning director and officer changes, and compensatory arrangements, can indicate internal shifts that may affect company strategy and performance.
Key Players & Entities
- Pacific Biosciences of California, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific leadership roles were affected by this amendment?
The filing pertains to the departure of directors, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the exact date of the earliest event reported in this amendment?
The earliest event reported is dated November 11, 2024.
What form type is this filing?
This filing is a Form 8-K/A, which is an Amendment No. 1 to a Current Report.
What is the Commission File Number for Pacific Biosciences of California, Inc.?
The Commission File Number is 001-34899.
What is the SIC code for Pacific Biosciences of California, Inc.?
The Standard Industrial Classification (SIC) code is 3826, for Laboratory Analytical Instruments.
Filing Stats: 807 words · 3 min read · ~3 pages · Grade level 12.6 · Accepted 2024-12-13 16:51:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market
- $485,000 — Eidel will receive (i) a lump of sum of $485,000 (less applicable withholding), which is
Filing Documents
- pacb-20241111.htm (8-K/A) — 27KB
- exhibit101-separationagree.htm (EX-10.1) — 82KB
- image_0.jpg (GRAPHIC) — 10KB
- 0001299130-24-000198.txt ( ) — 267KB
- pacb-20241111.xsd (EX-101.SCH) — 2KB
- pacb-20241111_lab.xml (EX-101.LAB) — 22KB
- pacb-20241111_pre.xml (EX-101.PRE) — 13KB
- pacb-20241111_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 Separation Agreement and Release, dated December 6, 2024 and effective December 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Brett Atkins Brett Atkins General Counsel Date: December 13, 2024